First Page | Document Content | |
---|---|---|
![]() Date: 2012-06-27 15:01:00Low molecular weight heparin Factor X Coagulation Protamine sulfate Partial thromboplastin time Vitamin A Biology Heparins Coagulation system Medicine | Add to Reading List |
![]() | M118, A NOVEL, RATIONALLY ENGINEERED LOW MOLECULAR WEIGHT HEPARIN, WITH POTENT ANTI-XA AND ANTI-IIA ACTIVITIES IS REVERSIBLE BY PROTAMINE SULFATE, AND MONITORABLE WITH ACT FOLLOWING MULTIPLE IV INJECTIONS I. Fier , M. ADocID: 19U9M - View Document |
![]() | Figure 2: Mean ACT with Increasing Dose of M118DocID: 19obY - View Document |
![]() | PLEASE TYPE POLICY TITLE HEREDocID: 17xHv - View Document |
![]() | Common drug is re-engineered to improve surgery outcomesDocID: 10EsE - View Document |
![]() | Monitoring of heparin and its low-molecular-weight analogs by silicon field effect Nebojsˇa M. Milovic´*, Jonathan R. Behr*, Michel Godin*, Chih-Sheng Johnson Hou†, Kristofor R. Payer‡, Aarthi Chandrasekaran*, PeteDocID: ZYn8 - View Document |